Review: Receptor Targeted Nuclear Imaging of Breast Cancer
Receptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2),...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/18/2/260 |
id |
doaj-303354e73665479295684925dc3800d6 |
---|---|
record_format |
Article |
spelling |
doaj-303354e73665479295684925dc3800d62020-11-24T23:26:37ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-01-0118226010.3390/ijms18020260ijms18020260Review: Receptor Targeted Nuclear Imaging of Breast CancerSimone U. Dalm0John Fred Verzijlbergen1Marion De Jong2Department of Radiology & Nuclear medicine, Erasmus MC, Wytemaweg 80, 3015CN Rotterdam, The NetherlandsDepartment of Radiology & Nuclear medicine, Erasmus MC, Wytemaweg 80, 3015CN Rotterdam, The NetherlandsDepartment of Radiology & Nuclear medicine, Erasmus MC, Wytemaweg 80, 3015CN Rotterdam, The NetherlandsReceptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), somatostatin receptor (SSTR), and the gastrin releasing peptide receptor (GRPR) are being investigated for this purpose. Expression of these targets is BC subtype dependent and information that can be gained from lesion visualization is dependent on the target; ER-targeting radiotracers, e.g., can be used to monitor response to anti-estrogen treatment. Here we give an overview of the studies currently under investigation for receptor targeted nuclear imaging of BC. Main findings of imaging studies are summarized and (potential) purposes of lesion visualization by targeting these molecular markers are discussed. Since BC is a very heterogeneous disease and molecular target expression can vary per subtype, but also during disease progression or under influence of treatment, radiotracers for selected imaging purposes should be chosen carefully.http://www.mdpi.com/1422-0067/18/2/260breast cancerreceptor targeted nuclear imagingSPECTPETGRPRSSTRERPRHER2 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Simone U. Dalm John Fred Verzijlbergen Marion De Jong |
spellingShingle |
Simone U. Dalm John Fred Verzijlbergen Marion De Jong Review: Receptor Targeted Nuclear Imaging of Breast Cancer International Journal of Molecular Sciences breast cancer receptor targeted nuclear imaging SPECT PET GRPR SSTR ER PR HER2 |
author_facet |
Simone U. Dalm John Fred Verzijlbergen Marion De Jong |
author_sort |
Simone U. Dalm |
title |
Review: Receptor Targeted Nuclear Imaging of Breast Cancer |
title_short |
Review: Receptor Targeted Nuclear Imaging of Breast Cancer |
title_full |
Review: Receptor Targeted Nuclear Imaging of Breast Cancer |
title_fullStr |
Review: Receptor Targeted Nuclear Imaging of Breast Cancer |
title_full_unstemmed |
Review: Receptor Targeted Nuclear Imaging of Breast Cancer |
title_sort |
review: receptor targeted nuclear imaging of breast cancer |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2017-01-01 |
description |
Receptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), somatostatin receptor (SSTR), and the gastrin releasing peptide receptor (GRPR) are being investigated for this purpose. Expression of these targets is BC subtype dependent and information that can be gained from lesion visualization is dependent on the target; ER-targeting radiotracers, e.g., can be used to monitor response to anti-estrogen treatment. Here we give an overview of the studies currently under investigation for receptor targeted nuclear imaging of BC. Main findings of imaging studies are summarized and (potential) purposes of lesion visualization by targeting these molecular markers are discussed. Since BC is a very heterogeneous disease and molecular target expression can vary per subtype, but also during disease progression or under influence of treatment, radiotracers for selected imaging purposes should be chosen carefully. |
topic |
breast cancer receptor targeted nuclear imaging SPECT PET GRPR SSTR ER PR HER2 |
url |
http://www.mdpi.com/1422-0067/18/2/260 |
work_keys_str_mv |
AT simoneudalm reviewreceptortargetednuclearimagingofbreastcancer AT johnfredverzijlbergen reviewreceptortargetednuclearimagingofbreastcancer AT mariondejong reviewreceptortargetednuclearimagingofbreastcancer |
_version_ |
1725554231733125120 |